|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2004-2-18
|
|
pubmed:abstractText |
Assessment of low-grade glioma treatment response remains as much of a challenge as the treatment itself. Proton magnetic resonance spectroscopy ((1)H-MRS) and imaging were incorporated into a study of patients receiving temozolomide therapy for low-grade glioma in order to evaluate and monitor tumour metabolite and volume changes during treatment. Patients (n=12) received oral temozolomide (200 mg m(-2) day(-1)) over 5 days on a 28-day cycle for 12 cycles. Response assessment included baseline and three-monthly magnetic resonance imaging studies (pretreatment, 3, 6, 9 and 12 months) assessing the tumour size. Short (TE (echo time)=20 ms) and long (TE=135 ms) echo time single voxel spectroscopy was performed in parallel to determine metabolite profiles. The mean tumour volume change at the end of treatment was -33% (s.d.=20). The dominant metabolite in long echo time spectra was choline. At 12 months, a significant reduction in the mean choline signal was observed compared with the pretreatment (P=0.035) and 3-month scan (P=0.021). The reduction in the tumour choline/water signal paralleled tumour volume change and may reflect the therapeutic effect of temozolomide.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/14970853-10213493,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14970853-10363566,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14970853-10414947,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14970853-10561351,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14970853-10576660,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14970853-10690719,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14970853-10944597,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14970853-11285548,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14970853-11300335,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14970853-12057095,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14970853-12447102,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14970853-12559880,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14970853-14630674,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14970853-1564535,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14970853-4334499,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14970853-7880611,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14970853-7931469,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14970853-8559376,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14970853-8637421,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14970853-8814162,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14970853-9322842
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0007-0920
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
23
|
|
pubmed:volume |
90
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
781-6
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:14970853-Administration, Oral,
pubmed-meshheading:14970853-Adult,
pubmed-meshheading:14970853-Antineoplastic Agents, Alkylating,
pubmed-meshheading:14970853-Brain Neoplasms,
pubmed-meshheading:14970853-Choline,
pubmed-meshheading:14970853-Dacarbazine,
pubmed-meshheading:14970853-Female,
pubmed-meshheading:14970853-Glioma,
pubmed-meshheading:14970853-Humans,
pubmed-meshheading:14970853-Magnetic Resonance Spectroscopy,
pubmed-meshheading:14970853-Male,
pubmed-meshheading:14970853-Treatment Outcome,
pubmed-meshheading:14970853-Water
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy.
|
|
pubmed:affiliation |
Cancer Research UK Clinical Magnetic Resonance Research Group, The Institute of Cancer Research and The Royal Marsden NHS Trust, Sutton, Surrey SM2 5PT, UK.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|
